Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R348 in Keratoconjunctivitis Sicca
NCT01900249Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Jul 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of R348 in keratoconjunctivitis sicca (KCS), sponsored by Rigel Pharmaceuticals, Inc.. Started Jul 2013; status: completed.
02
Drugs
R348
03
Conditions
keratoconjunctivitis sicca (KCS)
Beyond the preview
Go deeper on NCT01900249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01900249.